Weighing the Evidence: A Case-Based Review in Ulcerative Colitis - a podcast by ReachMD

CME credits: 0.25

Valid until: 25-03-2023

Claim your CME credit at https://reachmd.com/programs/cme/weighing-the-evidence-a-case-based-review-in-ulcerative-colitis/13439/

The proliferation of new classes of therapies for ulcerative colitis is affecting how we decide which treatments are most appropriate for our patients who are first- or second-line non-responders. This creates not only new challenges, but also new opportunities for all community gastroenterologists. Dr. Neil Nandi and Dr. David Rubin walk us through a case to highlight some of these challenges.

Since the completion of this activity, results from the ELEVATE UC 52 study, a yearlong phase 3 trial of etrasimod in moderate to severe ulcerative colitis, were announced. Etrasimod is an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator that showed positive 12- and 52-week results compared to placebo. Patients achieved statistically significant improvements in the co-primary endpoint of clinical remission at weeks 12 and 52 when compared to placebo. Statistically significant improvements were also attained in all key secondary endpoints at both 12 and 52 weeks. We will provide more data as the full results are published and presented in the future.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD